SIBPA 13
Alternative Names: Her3-ADC - Shanghai Institute Of Biological Products; SIBP-A13Latest Information Update: 13 Mar 2024
At a glance
- Originator Shanghai Institute of Biological Products
- Class Antibodies; Antineoplastics; Drug conjugates
- Mechanism of Action Antibody-dependent cell cytotoxicity
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 12 Mar 2024 Shanghai Institute Of Biological Products plans a phase I trial for Solid tumours (Late-stage disease, Metastatic disease, Second line therapy or greater) (IV, Infusion) in March 2024 (NCT06298058)
- 07 Mar 2024 Preclinical trials in Solid tumours in China (IV) before March 2024
- 18 Sep 2023 NMPA approves Clinical Trial Application for SIBPA 13 in Solid tumours